Document Type

Article

Publication Date

8-1-2024

Keywords

JGM, Humans, Tumor Microenvironment, Lung Neoplasms, Immunotherapy, Chemokines, Animals, Signal Transduction

JAX Source

Front Immunol. 2024;15:1443366.

ISSN

1664-3224

PMID

39114657

DOI

https://doi.org/10.3389/fimmu.2024.1443366

Grant

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA034196 to SP and by unrestricted funds from the Jackson Laboratory for Genomic Medicine to SP.

Abstract

The tumor microenvironment (TME) is a complex interconnected network of immune cells, fibroblasts, blood vessels, and extracellular matrix surrounding the tumor. Because of its immunosuppressive nature, the TME can pose a challenge for cancer immunotherapies targeting solid tumors. Chemokines have emerged as a crucial element in enhancing the efficacy of cancer immunotherapy, playing a direct role in immune cell signaling within the TME and facilitating immune cell migration towards cancer cells. However, chemokine ligands and their receptors exhibit context-dependent diversity, necessitating evaluation of their tumor-promoting or inhibitory effects based on tumor type and immune cell characteristics. This review explores the role of chemokines in tumor immunity and metastasis in the context of the TME. We also discuss current chemokine-related advances in cancer immunotherapy research, with a particular focus on lung cancer, a common cancer with a low survival rate and limited immunotherapy options.

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS